Chardan Capital raises Rocket's PT to $11, maintains Buy rating.

Chardan Capital raises Rocket's PT to $11, maintains Buy rating.

Chardan Capital has recently raised its target price for Rocket Pharmaceuticals (NASDAQ: RCKT) to $11.00 from $12.00, while maintaining a "buy" rating on the biotechnology company's stock. The new target price suggests a potential upside of 284.62% from the company's previous close, according to a report released on August 11, 2025 [1].

The brokerage firm also issued earnings estimates for Rocket Pharmaceuticals' fiscal year 2025 at ($2.01) EPS and for 2026 at ($1.19) EPS. These estimates reflect the ongoing financial challenges faced by the company, which reported a loss of ($0.59) earnings per share for the last quarter, missing the consensus estimate [1].

Rocket Pharmaceuticals has been the subject of various analyst reports. Bank of America reissued a "neutral" rating and set a $4.00 price target on the stock, while Wedbush reaffirmed an "outperform" rating and set a $32.00 price target. Needham & Company LLC and JPMorgan Chase & Co. reaffirmed their "hold" and "neutral" ratings, respectively. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price target. Overall, Rocket Pharmaceuticals currently has an average rating of "Hold" and an average target price of $16.33 [1].

Several institutional investors have recently increased their stakes in Rocket Pharmaceuticals. Geode Capital Management LLC, Wells Fargo & Company MN, Envestnet Asset Management Inc., Invesco Ltd., and Legal & General Group Plc boosted their holdings in the company during the fourth quarter of 2024. These holdings now account for 98.39% of the company's stock [1].

The company operates as a late-stage biotechnology firm focusing on gene therapies for rare and devastating diseases. Its clinical-stage ex vivo lentiviral vector programs include treatments for Fanconi anemia, leukocyte adhesion deficiency-I, and pyruvate kinase deficiency [1].

In contrast, Rocket Companies, Inc. (NYSE: RKT), a leading fintech platform, reported an earnings beat and revenue growth in the second quarter of 2025. The company's acquisition of Redfin and the pending COOP transaction are expected to bolster its financial performance [2].

References:

[1] https://www.marketbeat.com/instant-alerts/rocket-pharmaceuticals-nasdaqrckt-price-target-cut-to-1100-by-analysts-at-chardan-capital-2025-08-11/
[2] https://finance.yahoo.com/news/earnings-beat-acquisitions-strengthen-rocket-072119139.html